Hypotheses from other contexts, such as COVID-19, propose that upstream C3 blockade may exert broader immunological effects than terminal C5 inhibition, potentially influencing viral susceptibility (Mastellos et al., 2020). The gene discussed is C5; the disease is COVID-19.